HUTCHMED (China) Limited
HCMNASDAQHealthcare● Active
$10.81
$-0.06(-0.54%)
Market Cap$1.9B
P/E Ratio—
52W High$19.5
52W Low$10.8113
HUTCHMED (China) Limited (HCM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HCM · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 7, 2025EPS Actual
$1.30
Est. $1.46 · -11.0%
Revenue
$0.14B
Est. $0.33B · -58.0%
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 7, 2025
After Market Close
▼ Miss EPS▼ Miss Revenue
HCM reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $0.10 | — | — | — | $0.31B | — |
| ◌ Q2 FY2026 | Jun 4, 2026 | -$0.36 | — | — | — | $0.08B | — |
| ◌ Q1 FY2026 | Mar 5, 2026 | $2.50 | — | — | $0.27B | $0.29B | -6.7% |
| ▼ Q3 FY2025 | Aug 7, 2025 | $1.46 | $1.30 | -11.0% | $0.14B | $0.33B | -58.0% |
| — Q3 FY2025 | Jul 2, 2025 | — | $1.30 | — | $0.14B | — | — |
| ▲ Q1 FY2025 | Mar 19, 2025 | -$0.09 | $0.03 | +137.9% | $0.16B | $0.32B | -49.2% |
| — Q3 FY2024 | Sep 30, 2024 | — | $0.03 | — | $0.16B | — | — |
| — Q3 FY2024 | Jul 31, 2024 | — | $0.01 | — | $0.15B | $0.16B | -4.3% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$0.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 4, 2026
EPS Actual
—
EPS Est.
-$0.36
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 5, 2026
EPS Actual
—
EPS Est.
$2.50
EPS Surpr.
—
Revenue
$0.27B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
$1.30
EPS Est.
$1.46
EPS Surpr.
-11.0%
Revenue
$0.14B
Q3 FY2025
Jul 2, 2025
EPS Actual
$1.30
EPS Est.
—
EPS Surpr.
—
Revenue
$0.14B
Q1 FY2025
Mar 19, 2025Beat
EPS Actual
$0.03
EPS Est.
-$0.09
EPS Surpr.
+137.9%
Revenue
$0.16B
Q3 FY2024
Sep 30, 2024
EPS Actual
$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.16B
Q3 FY2024
Jul 31, 2024
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.15B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2029 | $0.14 | $0.14 | $0.14 | 1 |
| Q1 FY2029 | $0.42 | $0.42 | $0.42 | 1 |
| Q4 FY2028 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2028 | $0.10 | $0.10 | $0.10 | 1 |
| Q2 FY2028 | $2.50 | $2.50 | $2.50 | 1 |
| Q1 FY2028 | $1.46 | $1.46 | $1.46 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2029 | $0.5B | $0.5B | $0.5B | 1 |
| Q1 FY2029 | $0.5B | $0.5B | $0.5B | 1 |
| Q4 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
| Q2 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
| Q1 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2025 | Aug 7, 2025 | -11.0% | $17.93 | $16.31 | -9.04% |
| — Q3 FY2025 | Jul 2, 2025 | — | $15.41 | $15.69 | +1.82% |
| ▲ Q1 FY2025 | Mar 19, 2025 | +137.9% | $14.95 | $16.18 | +8.23% |
| — Q3 FY2024 | Sep 30, 2024 | — | $19.04 | $19.53 | +2.57% |
| — Q3 FY2024 | Jul 31, 2024 | — | $18.00 | $19.44 | +8.00% |
| — Q2 FY2024 | Jun 10, 2024 | — | $17.76 | $18.08 | +1.80% |
| ▲ Q1 FY2024 | Feb 28, 2024 | +96.3% | $15.99 | $15.21 | -4.88% |
| — Q3 FY2023 | Jul 31, 2023 | — | $14.72 | $14.07 | -4.42% |
Q3 FY2025-9.04%
Report Date
Aug 7, 2025
EPS Beat/Miss
-11.0%
Price Before
$17.93
Price After
$16.31
Q3 FY2025+1.82%
Report Date
Jul 2, 2025
EPS Beat/Miss
—
Price Before
$15.41
Price After
$15.69
Q1 FY2025+8.23%
Report Date
Mar 19, 2025
EPS Beat/Miss
+137.9%
Price Before
$14.95
Price After
$16.18
Q3 FY2024+2.57%
Report Date
Sep 30, 2024
EPS Beat/Miss
—
Price Before
$19.04
Price After
$19.53
Q3 FY2024+8.00%
Report Date
Jul 31, 2024
EPS Beat/Miss
—
Price Before
$18.00
Price After
$19.44
Q2 FY2024+1.80%
Report Date
Jun 10, 2024
EPS Beat/Miss
—
Price Before
$17.76
Price After
$18.08
Q1 FY2024-4.88%
Report Date
Feb 28, 2024
EPS Beat/Miss
+96.3%
Price Before
$15.99
Price After
$15.21
Q3 FY2023-4.42%
Report Date
Jul 31, 2023
EPS Beat/Miss
—
Price Before
$14.72
Price After
$14.07
Avg Beat Reaction+1.68%
Avg Miss Reaction-9.04%
Beat Rate2 / 8 quarters
Largest Move-9.04% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HCM ends December
HUTCHMED (China) Limited (HCM) most recently reported earnings on August 7, 2025 for Q3 FY2025, posting EPS of $1.30 — missing the analyst consensus of $1.46 by -11.0%. The next HCM earnings date is expected around September 1, 2026.
Each quarter, investors track HCM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HCM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HCM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HCM earnings · 5 questionsHUTCHMED (China) Limited's next earnings report is expected around September 1, 2026. HCM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HCM historically reports after market close (AMC).
HCM earnings datewhen is HCM earningsHCM next earnings datewhen does HCM report earningsHCM earnings calendar
▸ Source: FMP · HUTCHMED (China) Limited SEC filings · US GAAP · HUTCHMED (China) Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026